TY - JOUR
T1 - Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer
T2 - A case-control study
AU - De Stefano, Valerio
AU - Ghirardi, Arianna
AU - Masciulli, Arianna
AU - Carobbio, Alessandra
AU - Palandri, Francesca
AU - Vianelli, Nicola
AU - Rossi, Elena
AU - Betti, Silvia
AU - Di Veroli, Ambra
AU - Iurlo, Alessandra
AU - Cattaneo, Daniele
AU - Finazzi, Guido
AU - Bonifacio, Massimiliano
AU - Scaffidi, Luigi
AU - Patriarca, Andrea
AU - Rumi, Elisa
AU - Casetti, Ilaria Carola
AU - Stephenson, Clemency
AU - Guglielmelli, Paola
AU - Elli, Elena Maria
AU - Palova, Miroslava
AU - Rapezzi, Davide
AU - Erez, Daniel
AU - Gomez, Montse
AU - Wille, Kai
AU - Perez-Encinas, Manuel
AU - Lunghi, Francesca
AU - Angona, Anna
AU - Fox, Maria Laura
AU - Beggiato, Eloise
AU - Benevolo, Giulia
AU - Carli, Giuseppe
AU - Cacciola, Rossella
AU - McMullin, Mary Frances
AU - Tieghi, Alessia
AU - Recasens, Valle
AU - Isfort, Susanne
AU - Marchetti, Monia
AU - Griesshammer, Martin
AU - Alvarez-Larran, Alberto
AU - Vannucchi, Alessandro Maria
AU - Rambaldi, Alessandro
AU - Barbui, Tiziano
N1 - Publisher Copyright:
© 2020 by The American Society of Hematology.
PY - 2020/1/30
Y1 - 2020/1/30
N2 - Patients with Philadelphia-negative myeloproliferative neoplasm (MPN) are prone to the development of second cancers, but the factors associated with these events have been poorly explored. In an international nested case-control study, we recruited 647 patients with carcinoma, nonmelanoma skin cancer, hematological second cancer, and melanoma diagnosed concurrently or after MPN diagnosis. Up to 3 control patients without a history of cancer and matched with each case for center, sex, age at MPN diagnosis, date of diagnosis, and MPN disease duration were included (n 5 1234). Cases were comparable to controls for MPN type, driver mutations and cardiovascular risk factors. The frequency of thrombosis preceding MPN was similar for cases and controls (P 5 .462). Thrombotic events after MPN and before second cancer were higher in cases than in controls (11.6% vs 8.1%; P 5 .013), because of a higher proportion of arterial thromboses (6.2% vs 3.7%; P 5 .015). After adjustment for confounders, the occurrence of arterial thrombosis remained independently associated with the risk of carcinoma (odds ratio, 1.97; 95% confidence interval, 1.14-3.41), suggesting that MPN patients experiencing arterial events after MPN diagnosis deserve careful clinical surveillance for early detection of carcinoma.
AB - Patients with Philadelphia-negative myeloproliferative neoplasm (MPN) are prone to the development of second cancers, but the factors associated with these events have been poorly explored. In an international nested case-control study, we recruited 647 patients with carcinoma, nonmelanoma skin cancer, hematological second cancer, and melanoma diagnosed concurrently or after MPN diagnosis. Up to 3 control patients without a history of cancer and matched with each case for center, sex, age at MPN diagnosis, date of diagnosis, and MPN disease duration were included (n 5 1234). Cases were comparable to controls for MPN type, driver mutations and cardiovascular risk factors. The frequency of thrombosis preceding MPN was similar for cases and controls (P 5 .462). Thrombotic events after MPN and before second cancer were higher in cases than in controls (11.6% vs 8.1%; P 5 .013), because of a higher proportion of arterial thromboses (6.2% vs 3.7%; P 5 .015). After adjustment for confounders, the occurrence of arterial thrombosis remained independently associated with the risk of carcinoma (odds ratio, 1.97; 95% confidence interval, 1.14-3.41), suggesting that MPN patients experiencing arterial events after MPN diagnosis deserve careful clinical surveillance for early detection of carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=85078816507&partnerID=8YFLogxK
U2 - 10.1182/blood.2019002614
DO - 10.1182/blood.2019002614
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31869407
AN - SCOPUS:85078816507
SN - 0006-4971
VL - 135
SP - 381
EP - 386
JO - Blood
JF - Blood
IS - 5
ER -